Charmacy Pharmaceutical Co., Ltd. provided earnings guidance for the ended 31 December 2021. For the period, the group is expected to report a net profit attributable to the shareholders of the parent company of approximately RMB 21.00 million to RMB 25.00 million for the Year, representing a decrease of approximately 38% to 48% as compared with that of the year ended 31 December 2020.